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Abstract
Amyotrophic lateral sclerosis (ALS) is a lethal disease characterized by a progressive loss of motoneurons. The clinical
symptoms include skeletal muscle weakness and atrophy, which impairs motor performance and eventually leads to
respiratory failure. We tested whether dihydrotestosterone (DHT), which has both anabolic effects on muscle and
neuroprotective effects on axons and motoneurons, can ameliorate clinical symptoms in ALS. A silastic tube containing DHT
crystals was implanted subcutaneously in SOD1-G93A mice at early symptomatic age when decreases in body weight and
grip-strength were observed as compared to wild-type mice. DHT-treated SOD1-G93A mice demonstrated ameliorated
muscle atrophy and increased body weight, which was associated with stronger grip-strength. DHT treatment increased the
expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through
retrograde transport. DHT treatment attenuated neuromuscular junction denervation, and axonal and motoneuron loss.
DHT-treated SOD1-G93A mice demonstrated improvement in motor behavior as assessed by rota-rod and gait analyses, and
an increased lifespan. Application of DHT is a relatively simple and non-invasive procedure, which may be translated into
therapy to improve the quality of life for ALS patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a late onset neurodegen-
erative disease characterized by a progressive loss of motoneurons
in the brain and spinal cord. The clinical symptoms of ALS
include skeletal muscle weakness, atrophy and paralysis, which
eventually lead to fatal respiratory failure within 2–5 years from
the disease onset [1]. The majority of ALS cases are sporadic ALS
caused by unknown etiology, while about 10% of ALS cases are
the inherited form of ALS, called familial ALS (fALS). Recently,
mutations in TDP-43 and FUS/TLS, which are DNA/RNA-
binding proteins, were found in both types of ALS [2]. With
a higher frequency, mutations in the human superoxide dismutase
1 (SOD1) gene are found in about 20% of fALS patients, and
inserting these mutated human SOD1 genes into rodents have
generated ALS animal models [3]. SOD1 mutations induce a gain
of toxic function instead of a loss of enzymatic function, which
converts reactive superoxide into hydrogen peroxide and water to
reduce oxidative stress [4].
Furthermore, accumulating studies suggested that mutant
SOD1-mediated toxicity in non-neuronal cells such as skeletal
muscle and glial cells contribute to motoneuron degeneration in
ALS [1,5,6,7]. In accordance with the current notion that ALS is
a non-cell autonomous disease and involves multiple cell types,
inhibiting motoneuron death through Bax knock-out is not
sufficient to prevent clinical symptoms of ALS, particularly in
muscle [8]. Considering that muscle-related symptoms are closely
related with the quality of the patient’s life, targeting ALS-affected
muscle may provide practical benefits to patients.
As a therapeutic intervention to reduce muscle weakness and
atrophy, administration of androgens could be a potential strategy
due to their roles in increasing muscle size and strength [9,10,11].
Androgens have been used for anabolic therapies to treat muscle
wasting caused by chronic illness and aging [9]. However, it is not
known whether androgen treatment can also increase muscle mass
and strength in ALS patients who suffer from progressive muscle
atrophy and associated motor defects. It is interesting to note that
ALS patients show a lower level of free testosterone, which is
a bioavailable form of androgen, compared with a non-ALS
control group [12]. Since a low level of testosterone is associated
with reduced muscle mass and strength [13,14], it is possible that
reduced androgen observed in ALS patients may contribute to
muscle atrophy and weakness. Taken together, reduced androgen
level may play a role in reducing the size and strength of skeletal
muscle in ALS, and therefore androgen treatment might be one of
the therapeutic approaches to alleviate muscle symptoms.
In addition to anabolic effects on muscle, androgen may directly
benefit motoneurons through the highly expressed androgen
receptors (ARs) in the ventral horn of the spinal cord [15]. The
neuroprotective effects of androgens in promoting neuronal
survival and neurite outgrowth have been found in the spinal
motoneurons, and extensively in sexually dimorphic motoneurons
such as the spinal nucleus of the bulbocavernosus [16]. Particu-
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nerve crush by increasing the rate of nerve growth towards its
target hindlimb muscles [17,18]. Given that progressive motoneu-
ron death and ‘‘dying-back’’ axonal retraction are the manifested
pathology in ALS [19,20], androgens may delay disease pro-
gression through its neuroprotective effects.
To examine a potential therapeutic effect of androgens in ALS,
we administrated 5a-dihydrotestosterone (DHT), a metabolite of
testosterone, to SOD1-G93A mice. The SOD1- G93A transgenic
mouse is one of the extensively used animal models of ALS, which
replicates pathological courses of ALS patients. SOD1-G93A
transgenic mice demonstrate muscle atrophy and neuromuscular
junction denervation from ,50 days of age, ventral axon loss from
,80 days of age, and motoneuron death from ,100 days of age in
a ‘‘dying-back’’ fashion [19,20], and typically die at ,140 days of
age [21]. A silicon tubing containing DHT crystals was implanted
subcutaneously in SOD1-G93A mice at early symptomatic age to
mimic the time point when patients may receive treatments. In the
present study, we found that DHT treatment ameliorates
morphological defects in skeletal muscle, nerves, and motoneurons
in SOD1-G93A mice. The morphological improvement was
accompanied by enhanced motor performance and slightly
increased survival duration.
Materials and Methods
Ethics Statement
All procedures related to laboratory animals were performed
according to the US National Institutes of Health laboratory
animal care guidelines. The protocol was approved by the
Institutional Animal Care and Use Committee of the University
of Southern California (protocol #: 10981). All efforts were made
to minimize the suffering of animals.
Animals
We used SOD1-G93A mutant mice with the congenic C57BL/
6J background [B6.Cg-Tg (SOD1-G93A) 1Gur/J, Stock#
004435, The Jackson Laboratory], which exhibits a slightly longer
lifespan with a more consistent phenotype and the smallest
variation in survival than the extensively used hybrid line in
C57Bl6/SJL background [21]. Because there are differences in
disease progression, muscle size and strength in SOD1 mice
caused by gender [21,22], we administrated DHT only to male
mice to avoid any ambiguity caused by gender, which will also
avoid undesirable hormonal effects caused by androgen treatment
in female mice. SOD1-G93A mutant mice were cross-bred with
the same background mice expressing YFP in all motoneurons
(thy1-YFP mice, B6.Cg-TgN (Thy1-YFPH) 2Jrs, Jackson Labs) to
generate SOD1-G93A/YFP double transgenic mice for visualizing
motor nerves [23]. Since this double transgenic does not elicit any
changes in disease onset and progression in SOD1 mice [20], we
used both SOD1-G93A and SOD1-G93A/YFP mice for behav-
ioral studies. However, YFP expression in neurons may induce
molecular changes related to cell stress responses and might
modify abnormalities at neuromuscular junction (NMJ)s [24].
Therefore, it is important to compare molecular changes and NMJ
innervation exclusively among either YFP-expressing animals or
non-YFP animals. We used only SOD1-G93A/YFP mice for
morphological and molecular assays, so the differences observed
by DHT or orchidectomy were not affected by whether a mouse
expressed YFP or not. Mice were housed in a 12-hour light-dark
cycle, and given free access to food and water. Food and water
were provided on the floor of the cage once the mice could not
reach the food by themselves. For the morphological and
molecular analyses, animals were sacrificed at postnatal day 120
(P120), which was the symptomatic age showing marked reduction
in muscle weight and motor performance. The mice used for the
behavioral and survival analyses were sacrificed at the end-stage
when a mouse was not able to right itself within 30 s when placed
on one side. Mice were anesthetized via an intraperitoneal (i.p.)
injection with a mixture of xylazine (10 mg/kg body weight) and
Ketamine (80 mg/kg body weight).
DHT implant
Crystalline 5a-dihydrotestosterone (DHT) (Sigma) was admin-
istered in the form of silastic implant. One-cm length of silastic
medical tubing (0.078 cm-inner diameter/0.0125 cm- outer
diameter; Dow Corning Corporation) was filled with 5 mg of
DHT, and both ends were sealed with a silastic medical-grade
adhesive (Dow Corning). Silastic tubing without DHT was used as
a control. Before implanting the silastic tube, the tubes were
equilibrated in saline overnight. DHT-filled or empty silastic tubes
were implanted subcutaneously in the backs of anesthetized male
SOD1-G93A mice at P75. Based on the method of calculating
release dosage based on the surface area of the DHT-filled silastic
tube, the estimation of its plasma concentration was ,500 ng/dl
plasma, which is higher than normal physiological level [25].
Orchidectomy surgery
Mice were anesthetized via an intraperitoneal (i.p.) injection
with a mixture of Rompun (8 mg/kg body weight) and Ketamine
(80 mg/kg body weight). The scrotum was shaved, and a small
incision (0.5–1 cm) at the ventral midline was made. The tunica
was exposed by pushing skin away, and was pierced. The
spermatic artery was sutured, before removing testis to avoid
bleeding. After removing both testes, one or two stitches were
made to close the incision, and animals recovered on a 37uC
heating pad. Buprenex was administered (0.1 ml/20 gram, i. p.)
for analgesia after surgery. Surgical instruments were sterilized by
an autoclave prior to surgeries.
Histological examination of muscle and neuromuscular
junctions
The tibialis anterior (TA) and diaphragm (DIA) muscles were
dissected from SOD1-G93A/YFP double transgenic mice that
express YFP in motor nerves, and fixed with 4% paraformalde-
hyde for 30 min. To measure cross sectional area, total number of
muscle fibers, and the size of single muscle fiber, TA was rinsed in
phosphate-buffered saline (PBS) three times for 10 min and cryo-
protected in 30% sucrose overnight. TA muscles were embedded
in Tissue Tek O.C.T (Sakura Finetek), flash-frozen in supercooled
isopentane, and sectioned (16 mm thickness) on a cryostat. The
mid-belly areas were sectioned, and stained with monoclonal anti-
myosin (Sigma). The cross sectional areas of muscle fibers were
determined by using Image J (NIH Image). To examine NMJ
innervation, TA and DIA muscle were rinsed in PBS, and whole
muscles were teased and stained with Alexa-594-alpha-bungar-
otoxin (BTX) (Invitrogen, 1:2000) for acetylcholine receptor
(AChR) clusters. For a blinded analysis, each treatment was
coded by the investigator who collected muscles, and another
investigator examined 400–500 NMJs per muscle for NMJ
quantification without knowing to which group a particular
animal belonged.
Histological examination of motor axons
Ventral roots were collected from the lumbar segment 4 (L4)
that was fixed with 4% paraformaldehyde in 0.1 M phosphate-
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were collected by cutting the entry part of the nerves to the muscle
and fixed with 4% paraformaldehyde. Both ventral roots and
phrenic nerves were washed in 0.1 M phosphate buffer, and
further fixed with 1% osmium tetroxide for 2 h, dehydrated, and
embedded in Epon plastic (EM Sciences, Cincinnati, OH). Cross-
sections (1 mm-thickness) were stained with toluidine blue and
observed under light microscopy to measure axon numbers and
calibers with Image J (NIH image).
Histological examination of a-motoneurons
Animals were perfused with saline followed by 4% para-
formaldehyde in 0.1 M PBS. After the lumbar segments (L3-L5)
were dissected, they were rinsed in PBS, and cryo-protected in
30% sucrose overnight. Lumber segments were embedded in
Tissue Tek O.C.T (Sakura Finetek), flash-frozen in supercooled
isopentane, and sectioned (25 mm-thickness) on a cryostat. Every
5
th section from the serial cross-sections was stained with anti-
choline acetyltransferase (ChAT) antibody (Chemicon, 1:200) to
label a-motoneurons (determined by cell body size $250 mm
2).
About 15–20 sections summing to about 200–300 motoneurons
for each spinal cord were counted.
Quantitative RT-PCR analysis
Total RNA was extracted from the tibialis anterior muscle by
using TRIzol reagent (Invitrogen), and treated with DNase by
using DNA-free kit (Ambion). Two mg of total RNA measured
with a spectrophotometer at 260 nm absorbance was reverse-
transcribed using the SuperScript III (Invitrogen) for a synthesis of
complementary DNA (cDNA). cDNA was diluted in 1:20, and
5 ml of diluted cDNA was used in each 20 ml PCR reaction. Real-
time quantitative PCR (qPCR) was performed with SYBR green
dye using DNA Engine Opticon 2 system (Bio-Rad) with
a program of 40 cycles of 95uC 20 sec, 60uC 20 sec, 72uC
30 sec. The relative expression level for each gene was calculated
using the 2 -DDCt method [26], and all expression values were
normalized to housekeeping genes, such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) or b-actin.
The sequence of the primers as follows:
Insulin-like growth factor (IGF)-1: forward, 59- CTGGACCA-
GAGACCCTTTGC, reverse, 59- GGACGGGGACTTCT-
GAGTCTT; IGF-2: forward, 59- GTGCTGCATCGCTGCT-
TAC, reverse, 59- ACGTCCCTCTCGGACTTGG; Muscle ring
finger (MuRF)-1: forward, 59-ACCTGCTGGTGGAAAACATC,
reverse, 59-CTTCGTGTTCCTTGCACATC; GAPDH: for-
ward, 59- TGCATCCTGCACCACCAACT, reverse, 59-
ATGCCTGCTTCACCACCTTC; b-actin: forward, 59-
GGCTGTATTCCCCTCCATCG, reverse, 59- CCAGTTGG-
TAACAATGCCATGT.
Behavioral tests
Mice were monitored every 5 days for measuring their body
weights, and perform behavioral tests. For the grip-strength
analysis, mice were allowed to grasp a triangular pull bar from the
grip strength meter (Columbus Instruments). Once a mouse made
a stable grip with the pull bar, the mouse was slowly pulled away
from the pull bar until the grip was released. Maximum tension of
the pull bar was digitally recoded with the grip strength meter.
Five measurements were taken from each animal, and the mean
values were used for statistical analysis. For the rota-rod test,
a mouse was placed on a rotating rod that rotates at a speed of
11 rpm, and the latency until a mouse falls from the rod was
recorded. The longest latency (in sec) in 3 trials was recorded. For
the footprint analysis, hindlimbs were placed into non-toxic paints
and the animal was allowed to walk on a 50 cm length of paper,
and their continuous locomotion was recorded. Step length was
measured by dividing the walking distance by the number of steps
taken within the walking distance.
Statistical Analysis
All data are expressed as the mean 6 SEM. All statistical
analyses were performed on PRISM 5.01 software (Graph-Pad,
San Diego), using two-tailed student’s t-tests, except a two-way
ANOVA for analyzing muscle fiber distribution and the rota-rod
test. Kaplan-Meier method was used to create survival curves, and
log-rank (Mantel-Cox) test was used for comparing the difference
in survival. Significance was defined as p,0.05.
Results
DHT implant successively increases androgen level in
wild-type and SOD1-G93A mice
We used a DHT-filled silastic tube, which is an extensively used
method to release hormones systemically [17,25], to increase the
concentration of DHT in our study. We thus first tested whether
the implant can successively administrate DHT by implanting
DHT-filled tubes in wild-type mice at postnatal day 75 (P75).
Empty silastic tubes were also implanted in age-matched
littermates, which served as a control to exclude any possible
artifact caused by the implant surgery. To examine whether the
DHT implant increased androgen concentration, the weight of
seminal vesicles was measured at P120. Compared to a direct
measurement of DHT concentration in serum, which can be
affected by anesthesia and stress during blood collection [27,28],
measuring the seminal vesicle weight is a sensitive, albeit indirect,
way to assess the androgen level [13]. As shown in Fig. 1A and B,
DHT treatment in wild-type mice caused about a 20% increase in
the seminal vesicle weight compared with control wild-type mice.
As a reverse way to examine the sensitivity of the seminal vesicle to
androgen concentration, we attempted to decrease androgen
concentration by performing orchidectomy in wild-type mice, and
checked whether the seminal vesicle weight decreased. After
removing at P75 both testicles, which generate androgens, we
found a 79% reduction in the seminal vesicle weights in wild-type
mice (Fig. 1A), indicating that the seminal vesicle weight is
sensitive to androgen concentration. DHT implant in orchidecto-
mized wild-type mice recovered the seminal vesicle weight to the
normal level (Fig. 1A), which confirms a successful administration
of DHT through the implant.
Since it was reported that ALS patients show a lower level of the
bioavailable form of testosterone compared with a non-ALS
control group [12], we examined whether the seminal vesicle
weight of SOD1-G93A mice is smaller than that of wild-type mice.
As shown in Fig. 1A, SOD1-G93A mice showed a 20% lower
seminal vesicle weight compared with wild-type mice (SOD1-
G93A: 105.864.6 mg, WT: 132.166.4 mg, p=0.0039), which
reflects a lower androgen level in SOD1-G93A mice compared
with wild-type mice. To test whether DHT implant can also
increase androgen level in SOD1-G93A mice, we implanted
DHT-filled silastic tube at P75, and found that the DHT implant
increased the seminal vesicle weight in SOD1-G93A mice by 38%
(SOD1-G93A+DHT: 146.165.5 mg, p=0.0003, Fig. 1A and B).
Conversely, orchidectomy in SOD1-G93A mice caused an 80%
reduction in seminal vesicle weight (SOD1-G93A+Orx.:
20.863.5 mg, p,0.0001) compared with control SOD1-G93A
mice, and DHT treatment to orchidectomized SOD1-G93A mice
was able to restore the seminal vesicle weights comparable to
control SOD1-G93A mice (SOD1-G93A+Orx.+DHT:
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demonstrate lower seminal vesicle weight, which reflects the lower
concentration of androgens compared with wild-type mice. Also,
we confirmed that the DHT implant could successively release
DHT, which was reflected by the increase in seminal vesicle
weight.
DHT attenuates skeletal muscle atrophy in SOD1-G93A
mice
To examine whether DHT treatment attenuates skeletal muscle
atrophy in SOD1-G93A mice, we measured the weight of
gastrocnemius (GN) and tibialis anterior (TA), which are
vulnerable muscles in ALS [29,30]. Muscle atrophy in GN and
TA muscles was observed in SOD1-G93A mice by showing a 44%
and a 49% decreased muscle weight, respectively, compared with
wild-type mice (Fig. 2A and B). DHT treatment increased the GN
muscle weight by 32% (SOD1-G93A+DHT: 147.564.5 mg,
SOD1-G93A: 111.466.6 mg, p,0.001, Fig. 2A), and the TA
muscle weight by 43% (SOD1-G93A+DHT: 46.362.4 mg,
SOD1-G93A: 32.562.5 mg, p=0.0017, Fig. 2B). Conversely,
orchidectomized SOD1-G93A mice with lower androgen concen-
tration showed a decrease in the muscle weight of GN and TA by
25% and 22%, respectively (GN: 83.465.7 mg, TA:
25.262.4 mg, Fig. 2A and B). A similar pattern of increase or
decrease in muscle weight by DHT treatment or orchidectomy,
respectively, was observed in wild-type mice as well (Fig. 2A and
B).
To examine whether the increase in muscle weight by DHT
treatment is associated with the increase in cross-sectional area, we
measured the cross-sectional area of TA muscle. Compared to
control SOD1-G93A mice, DHT-treated SOD1-G93A mice
demonstrated 22.3% increase in cross-sectional area in TA
muscles (SOD1-G93A+DHT: 3.2360.19 mm
2, SOD1-G93A:
2.6460.03 mm
2, p=0.034, Fig. 2C). Similar to the decrease in
muscle weight by orchidectomy, we found that orchidectomy
decreased the cross-sectional area of TA muscle (SOD1-
G93A+Orx.: 2.0960.11 mm
2, p,0.01, Fig. 2C). To further
examine whether the differences in cross-sectional area are caused
by the differences in the number and/or the area of muscle fibers,
we analyzed total muscle fiber numbers and muscle fiber areas of
TA muscles. As shown in Fig. 2D, the total numbers of muscle
fibers in TA muscles were not significantly different among
orchidectomized, control, and DHT-treated SOD1-G93A mice,
although there was a trend of containing more muscle fibers in
association of higher androgen concentration. However, DHT
treatment significantly increased the muscle fiber area, while
orchidectomy decreased the muscle fiber area in TA muscles
(Fig. 2E and F). There was a shift toward a larger area of single
muscle fiber in DHT-treated SOD1-G93A mice, and a shift
toward a smaller muscle fiber area in orchidectomized SOD1-
G93A mice compared with control SOD1-G93A mice (p,0.01,
Fig. 2F).
DHT increases body weight and muscle strength in
SOD1-G93A mice
To examine whether increased muscle weight and size through
a DHT implant was associated with the increase in body weight,
we measured the body weight of SOD1-G93A mice. As shown in
Fig. 3A, DHT-treated SOD1-G93A mice demonstrated heavier
body weights compared with control SOD1-G93A mice
(p,0.001), although it was not able to be rescued to the level of
wild-type mice. Decreased androgen concentration in SOD1-
G93A mice by orchidectomy led to further reduction in body
weights compared with control SOD1-G93A mice (p=0.045,
Fig. 3A).
Increased muscle mass mediated by androgens has been shown
to be correlated with increased muscle strength [11,31,32].
Therefore, we examined whether increased muscle mass through
DHT treatment is accompanied by enhanced muscle strength in
SOD1-G93A mice. To assess muscle strength, we employed the
Figure 1. DHT increases whereas orchidectomy decreases the
seminal vesicle weight in wild-type and SOD1-G93A mice. A:
The weight of seminal vesicles was measured after removing the
adhering tissue and fluid. Wild type (WT) mice and SOD1-G93A (SOD1)
mice were implanted with either a DHT-filled or an empty silastic tube.
Orchidectomy and/or silastic tube implant was performed at postnatal
day 75 (P75), and the seminal vesicle weight was measured at P120.
DHT-treated WT mice showed a 19% increase in seminal vesicle weight
(156610.6 mg, p =0.042) compared with control WT mice
(132.166.4 mg). In SOD1 mice, the DHT-filled silastic tube also
increased the seminal vesicle weight by 38% (146.165.5 mg,
p=0.0003) compared with control SOD1 mice (105.864.6 mg).
Conversely, orchidectomy decreased the seminal vesicle weight in
both WT mice (28.4613 mg, p,0.0001) and SOD1 mice (20.863.5 mg,
p,0.0001) compared with control WT and SOD1 mice, respectively.
SOD1 control mice showed 20% reduced seminal vesicle weight
compared with WT control mice (p=0.0039). Sample size is indicated in
( ) for each group. Data are mean 6 SEM. # p,0.05, ### p,0.001
(compared with age-matched WT mice), ** p,0.01, ***p,0.001
(compared with control SOD1 mice). B: WT and SOD1 mice were
implanted with either a DHT-filled or an empty silastic tube at P75, and
the seminal vesicles were obtained at P120. Representative pictures of
the seminal vesicles are shown. Scale bar=5 mm.
doi:10.1371/journal.pone.0037258.g001
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mice were implanted with either a DHT-filled or an empty silastic tube, or orchidectomized at P75, and the morphological analyses were made at
P120. A: In WT mice, DHT increased the GN weight by 7% (212.468.8 mg), whereas orchidectomy decreased it by 14% (171.469.0 mg) compared
with control WT mice (198.465.5 mg). In SOD1 mice, DHT increased the GN weight by 32% (147.564.5 mg, p=0.00017), whereas orchidectomy
decreased it by 25% (83.465.7 mg, p=0.0086) compared with control SOD1 mice (111.466.6 mg). B: In WT mice, DHT increased the weight of TA
muscle by 12% (71.262.5 mg), whereas orchidectomy decreased it by 12% (56.163.6 mg) compared with control WT mice (63.661.5 mg). In SOD1
mice, DHT increased the weight of TA muscle by 43% (46.362.4 mg, p=0.0017), whereas orchidectomy decreased it by 22% (25.262.4 mg, p=0.05)
compared with control SOD1 mice (32.562.5 mg). Sample size is indicated in ( ) for each group. ## p,0.01, ### p,0.01 (compared with age-
matched WT mice), ** p,0.01, ***p,0.001 (compared with control SOD1 mice). C: DHT increased the cross-sectional area of TA muscle by 22.3%
(3.2360.19 mm
2,n=3 ,p=0.034), whereas orchidectomy decreased it by 20.8% (2.0960.11 mm
2,n=3 ,p=0.008) compared with control SOD1 mice
(2.6460.03 mm
2, n=3). D: DHT did not cause a significant increase in the muscle fiber number (4.8% increase, 3020.76152.2, p=0.49). Likewise,
orchidectomy did not cause a significant decrease in the muscle fiber number (7.0% decrease, 2681.0686.9, p=0.19) compared with control SOD1
mice (2883.7697.0). E: Representative pictures of the cross sectional area of TA muscles are shown. Scale bar=50 mm. F: Distribution of the area of
single muscle fiber is shown. Per TA muscle, 600–900 muscle fibers were measured, and 3 TA muscles per each treatment group were used for the
analysis of muscle fiber area. DHT treatment shifted the area of muscle fibers toward larger areas (1070.8639.8 mm
2, p=0.032), whereas
orchidectomy shifted it toward smaller areas (729.1661.9 mm
2, p=0.023) compared with control SOD1 mice (904.7626.6 mm
2). Data are mean 6
SEM. p,0.001 (2 way-ANOVA).
doi:10.1371/journal.pone.0037258.g002
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generated by the grip of a mouse on the pull bar. As shown in
Fig. 3B, SOD1-G93A mice exhibited 40% reduced grip-strength
compared with wild-type mice at P90, and the grip-strength
gradually weakened to reach only 20% of wild-type grip-strength
at P120. DHT treatment increased grip-strength by about 20%
stronger at P90 and 200% stronger at P120 in SOD1-G93A mice
(Fig. 3B).
DHT increases the expression of insulin-like growth factor
(IGF) -1 and -2, whereas decreases the expression of
MuRF-1 in skeletal muscle of SOD1-G93A mice
Increased skeletal muscle mass through androgens is known to
be mediated by insulin-like growth factor (IGF-1), which induces
myoblast proliferation, differentiation, and hypertrophy
[33,34,35,36]. To examine whether DHT increases IGF-1
expression in skeletal muscle of SOD1-G93A mice, we performed
quantitative RT-PCR. As shown in Fig. 4A, DHT treatment
increased the expression of IGF-1 by about 4-fold (p=0.0261) in
the TA muscle compared with control SOD1-G93A mice at P120.
Similarly, the expression level of IGF-2, which plays a similar role
in muscle to IGF-1 [37,38], was also increased by about 2-fold
(p=0.015) in DHT-treated SOD1-G93A mice compared with
control SOD1-G93A mice (Fig. 4A).
Another mechanism associated with muscle size is the
ubiquitin–proteasome system, which leads to degradation of
muscle proteins. Especially, Muscle RING Finger1 (MuRF-1),
a muscle-specific ubiquitin ligase, is required to induce rapid
muscle atrophy [39,40]. Therefore, we tested whether ameliorated
muscle atrophy in DHT-treated SOD1-G93A mice was associated
with the decreased expression of MuRF-1. By using quantitative
RT-PCR, we found that there was a trend that DHT treatment
decreased the expression of MuRF-1 by 43.9% compared with
control SOD1-G93A mice (p=0.198, Fig. 4B), which implies that
molecular pathway that triggers muscle atrophy might be
attenuated by DHT treatment. In summary, myotrophic pathway
mediated by IGF-1 and -2 was enhanced, while muscle wasting
Figure 3. DHT increases body weight and muscle strength in SOD1 mice. A: DHT-treated SOD1 mice showed heavier body weight
compared with control SOD1 mice (p,0.001), although it was still lower than the weight of WT mice throughout all time points. Orchidectomized
SOD1 mice demonstrated reduced body weights compared with control SOD1 mice (p=0.045). Data are mean 6 SEM. B: The grip-strength meter
was used to assess the muscle strength, and the maximum tension generated by the grip of a mouse on the pull bar was recorded. SOD1 mice
exhibited diminished grip-strength compared with WT mice throughout all time points examined (p,0.0001). DHT-treated SOD1 mice showed
stronger grip-strengths compared with control SOD1 mice (p,0.001), and the gap between these two groups gradually increased as age advanced.
Data are mean 6 SEM.
doi:10.1371/journal.pone.0037258.g003
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SOD1-G93A mice compared with control SOD1-G93A mice.
DHT improves the neuromuscular junction (NMJ)
innervation in SOD1-G93A mice
Together with muscular atrophy, denervation at the NMJs is
a prominent symptom found in skeletal muscle of ALS [19,29]. To
visualize NMJs, we used double transgenic mice SOD1-G93A/
YFP, which express fluorescent protein in all motor nerves. As
shown in Fig. 5A and B, SOD1-G93A/YFP mice showed a 77%
denervated or partially innervated NMJs in TA muscle at P120.
DHT treatment decreased the denervated NMJs by 56% in the
TA muscle, and increased the fully innervated NMJs by 2-fold
(p=0.02, p=0.049, respectively, Fig. 5Ab and B). Conversely,
decreasing androgen concentration through castration showed
about 70% less fully innervated NMJs in the TA muscle in
orchidectomized SOD1-G93A/YFP mice compared with control
SOD1-G93A/YFP mice (p=0.058, Fig. 5Ac, and B). We further
examined denervation in the diaphragm muscle (DIA) that causes
fatal respiratory failures in ALS patients. As shown in Fig. 5C,
DHT-treated SOD1-G93A/YFP mice exhibited a 24% increase
in fully innervated NMJs, and a 64% decrease in denervated NMJs
compared with control SOD1-G93A/YFP mice (p=0.0039,
p=0.014, respectively). Taken together, DHT treatment amelio-
rates NMJ denervation in SOD1-G93A mice, which may
contribute to improved muscle phenotype and motor function.
DHT ameliorates axonal degeneration in SOD1-G93A
mice.
To further examine whether the beneficial effect of DHT at
NMJs is accompanied by improved morphology in nerves, we
checked the phrenic nerve at the entry of the diaphragm muscle.
In SOD1-G93A mice, we found about a 40% loss in myelinated
axons in the phrenic nerves compared with wild-type mice at P120
[SOD1-G93A:184.6610.9, WT: 313.0611.5, p=0.0003 (Fig. 6A
and B)]. Compared with control SOD1-G93A mice, DHT-treated
SOD1-G93A mice exhibited 26% more myelinated axons in the
phrenic nerves [SOD1-G93A+DHT: 232.3616.8, p=0.043
(Fig. 6A and B)].
The effect of DHT in protecting nerves innervating hindlimb
muscles was also observed by checking the myelinated axon
number in the ventral root of the lumbar spinal cord. In SOD1-
G93A mice, about a 30% decrease in the total number of
myelinated axons was observed at the ventral root of L4 compared
with wild-type mice at P120 [SOD1-G93A: 691.2643.6, WT:
996.5658.5, p=0.0012 (Fig. 6C and D)]. It has been reported that
large caliber axons are preferentially affected by ALS [41,42], and,
indeed, we found a 43% reduction in the number of large caliber
axons in SOD1-G93A mice compared with wild-type mice [SOD:
404.2631.1, WT: 706.5651.6, p=0.0005 (Fig. 6D)]. Compared
with control SOD1-G93A mice, there were 24% more of total
myelinated axons in DHT-treated SOD1-G93A mice
(859.6653.4, p=0.013), which contained 36% more of large
caliber axons (547.8622.2, p=0.006, Fig. 6C and D). Conversely,
orchidectomized SOD1-G93A mice showed 10% less total
myelinated axons (622.3629.6, p=0.01, Fig. 6C and D) compared
with control SOD1-G93A mice.
DHT improves motoneuron survival in SOD1-G93A mice
To examine whether DHT treatment increased motoneuron
survival, we labeled the spinal cord sections with a choline
acetyltransferase (ChAT) antibody to visualize motoneurons. We
found about a 40% reduction in the number of motoneurons in
the lumbar spinal cord (L3–L5) of SOD1-G93A mice compared
with wild-type mice at P120 [SOD1-G93A: 13.960.7, WT:
23.860.9, p,0.0001 (Fig. 7A and B)]. Compared with control
SOD1-G93A mice, DHT-treated SOD1-G93A mice showed 27%
more motoneurons in the lumbar spinal cord [SOD1-
G93A+DHT: 17.760.8, p=0.0093 (Fig. 7A and B)]. In the
cervical spinal cord, which contains motoneurons innervating the
diaphragm muscle, we also found 18% more motoneurons in
DHT-treated SOD1-G93A mice compared with control SOD1-
G93A mice [SOD1-G93A+DHT: 19.960.4, SOD1-G93A:
16.860.7, p=0.47 (Fig. 7 B)].
DHT improves motor performance and survival in SOD1-
G93A mice
To determine whether the improved morphological features in
DHT-treated SOD1-G93A mice would lead to functional
improvement, we tested the effects of DHT treatment in motor
behavior and survival of SOD1-G93A mice. In addition to the
grip-strength analysis (Fig. 3B), which we previously performed in
relation to muscle mass, we further employed rota-rod and
footprint analyses as more global assessments of functional
outcome. The rota-rod test requires an ability to balance on the
rotating rod in addition to muscle strength. Although both DHT-
treated and control SOD1-G93A mice showed a similar decline of
motor function in the rota-rod test, the gap between two groups
increased as disease progressed (Fig. 8A). For example, DHT-
treated SOD1-G93A mice stayed 40% longer on the rotating rod
Figure 4. DHT increases the expression of insulin-like growth
factor -1 and -2, while decreases MuRF-1 expression. A: The TA
muscles were collected from DHT-treated SOD1 and control SOD1 mice
at P120 to check the expression of insulin-like growth factor (IGF) -1 and
IGF-2 through quantitative RT-PCR. DHT-treated SOD1 mice showed
increased expression of IGF-1 and IGF-2, by approximately 4-fold
(p=0.0261), and 2-fold (p=0.015), respectively, compared with control
SOD1 mice. *p,0.05. B: By using quantitative RT-PCR, we found that
DHT-treated SOD1 mice showed a trend of decreased expression of
MuRF-1 by 44% compared with control SOD1 mice (p=0.198).
doi:10.1371/journal.pone.0037258.g004
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p=0.043). To perform footprint analysis, which are used to detect
impaired motor behavior [43], the paws of SOD1-G93A mice
were placed into non-toxic paints and allowed to walk on a paper.
As shown in Fig. 8B, a DHT-treated SOD1-G93A mouse
displayed a longer step length compared with a littermate control
SOD1-G93A mouse at P100. Analysis of step length illustrates that
DHT-implanted SOD1-G93A mice displayed a longer step length
compared with control SOD1-G93A mice during disease pro-
gression (p=0.003, Fig. 8C). Consistent with the ameliorated
motor dysfunction observed in DHT-treated SOD1-G93A mice,
the mean survival duration after drug treatment was increased by
about 11% in DHT-treated SOD1-G93A mice (82.962.9 days)
compared with control SOD1-G93A mice (74.862.2 days)
(Fig. 8D). The overall lifespan of DHT-treated SOD1-G93A mice
also showed a slight, but significant increase by 5% (157.962.9
days, n=18), as compared to control SOD1-G93A mice
(149.862.2 days, n=24) (p=0.0174; log-rank test, Fig. 8E). In
summary, DHT treatment delayed motor impairment as assessed
by the rota-rod, grip-strength, and foot-print analyses, and
moreover extended lifespan in SOD1-G93A mice.
Discussion
The present study demonstrated that DHT alleviated the
pathological symptoms found in the skeletal muscle of SOD1-
G93A mice, which includes muscle atrophy and weakness. In
addition, DHT ameliorated neuromuscular pathology and de-
generation in axons and motoneurons. Moreover, these improved
morphological characteristics were linked with improved motor
behaviors and extended lifespan. The beneficial effect of DHT
Figure 5. DHT ameliorates denervation at neuromuscular junctions SOD1 mice. SOD1/YFP double transgenic mice expressing yellow
fluorescence protein (YFP) in all motor nerves were implanted with either a DHT-filled or an empty silastic tube, or orchidectomized at P75, and the
TA muscle and the diaphragm (DIA) muscle were collected at P120, and stained with anti-a-bungarotoxin to label post-synaptic acetylcholine
receptor (AChR) clusters. A: When a pre-synaptic nerve terminal (in green) fully overlaps with the post-synaptic AChR clusters (in red), the
neuromuscular junction (NMJ) is defined as a ‘‘fully innervated NMJ’’ (d). However, if a nerve terminal is partially overlapped with AChR, or is
completely absent, leaving only AChR, the NMJ is defined as a ‘‘partially innervated NMJ’’ (e) or a ‘‘denervated NMJ’’ (f), respectively. DHT-treated
SOD1/YFP mice (b) showed improved NMJ innervation in the TA muscle compared with control SOD1/YFP mice (a). However, orchidectomy in SOD1/
YFP mice aggravated denervation at NMJs (c). B: Quantification of NMJs at P120 in the TA muscle of DHT-treated, control, and orchidectomized
SOD1/YFP mice is shown. Compared to control SOD1/YFP mice, which showed 22.365.7% of fully innervated NMJs, DHT-treated SOD1/YFP mice
showed 47.3614.1% of fully innervated NMJs. Orchidectomized SOD1/YFP mice showed only 9.663.4% of fully innervated NMJs. C: Quantification of
NMJs at P120 in the DIA muscle of DHT-treated, and control SOD1/YFP mice is shown. Compared to SOD1/YFP mice, which showed 65.265.6% of
fully innervated NMJs, DHT-treated SOD1/YFP mice showed 81.065.5% of fully innervated NMJs. Data are mean 6 SEM. *p,0.05.
doi:10.1371/journal.pone.0037258.g005
Dihydrotestosterone Delays ALS Disease Progression
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37258Figure 6. DHT attenuates axonal loss in the phrenic nerve and ventral root of the spinal cord. A: The phrenic nerve at the entry of the
diaphragm muscle was sectioned to observe myelinated axons at P120. Representative pictures of the phrenic nerve from WT, control SOD1, and
DHT-treated SOD1 mice are shown. B: Quantification of myelinated axon number in the phrenic nerves is shown. The number of myelinated axons in
the phrenic nerve of SOD1 mice (184.6610.9) is about 40% less compared with WT mice (313.0611.5, p=0.0003). DHT-treated SOD1 mice showed
26% more myelinated axons (232.3616.8, p=0.043) compared with control SOD1 mice. Sample size is indicated in ( ) for each group. *p,0.05
(compared with control SOD1 mice), ### p,0.001 (compared with WT mice). C: Representative cross-sectional pictures of the ventral roots of the
spinal cord lumbar 4 segment from WT, control SOD1, DHT-treated SOD1, and orchidectomized SOD1 mice at P120 are shown. D: Quantification of
myelinated axon number in the ventral root of the lumbar 4 spinal cord is shown. The total number of myelinated axons in control SOD1 mice
(691.2643.6) is about 30% less compared with that in WT mice (996.5658.5, p=0.0012). DHT-treated SOD1 showed 24% more total myelinated axon
number compared with control SOD1 mice (859.6653.4, p=0.013). Especially, the number of the large caliber axons ($4 mm) were 43% less in SOD1
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including its effect on muscle, muscle-mediated retrograde trans-
port, and its direct effect on motoneurons.
The anabolic effect of DHT on skeletal muscle
Although muscle atrophy and weakness are the clinical
symptoms linked with functional capacity of ALS patients, there
is currently no effective treatment for these clinical symptoms.
Since increased motoneuron survival is not sufficient to maintain
NMJ innervation and motor function [8,44], a therapy that can
intervene in muscle symptoms needs to be considered for
a practical benefit to patients. In the present study, we
demonstrated that increased androgen level by DHT treatment
can ameliorate muscle atrophy and also improve muscle strength
in SOD1-G93A mice. The protective effect of androgen in
maintaining muscle mass and function was also observed in mice
that underwent orchidectomy, which results in muscle wasting and
weakness [13].
Contrary to the beneficial effects of androgens, decreasing
androgen was suggested as a therapy for another late-onset
motoneuron disease called spinal bulbar muscular atrophy
(SBMA), which also demonstrates muscle weakness and atrophy
[45,46]. Although SBMA and ALS share some clinical symptoms,
unlike ALS, SBMA expresses aberrant androgen receptor (AR),
which contains an expansion of the polyglutamine track caused by
CAG repeats in the first exon of the AR gene [47]. Since androgen
induces toxic nuclear accumulation of mutant ARs [48], androgen
treatment aggravates symptoms of SBMA and would cancel out
potential beneficial effects of androgen that we observed in the
present study.
Besides AR, androgens also modulate muscle through an AR-
independent pathway. Androgen withdrawal through castration
resulted in a 200% decrease in GN muscle weight in mice lacking
AR in limb muscles [49]. It was suggested that reduced expression
of IGF-1 upon castration is responsible for the decrease in muscle
mass. In fact, IGF-1 has been suggested as a candidate molecule
that mediates androgen-induced muscle growth [50,51]. Muscle-
specific overexpression of IGF-1 and intramuscular injection of
IGF-1 expressing viral vector demonstrated marked effect in
increasing skeletal muscle [36,52]. Since we observed that DHT
treatment in SOD1-G93A mice increased IGF-1 expression in
skeletal muscle (Fig 4A), it is possible that DHT ameliorated
muscle atrophy through IGF-1 and its downstream signaling
mice (404.2631.1) compared with WT mice (706.5651.6, p=0.0005). DHT-treated SOD1 mice showed 36% more large caliber axons ($4 mm)
(547.8622.2, p=0.006) compared with control SOD1 mice. Orchidectomized SOD1 mice showed 10% less total myelinated axon number compared
with control SOD1 mice (622.3629.6, p=0.01). Sample size is indicated in ( ) for each group. Data are mean 6 SEM. *p,0.05, ** p,0.01 (compared
with the total myelinated axon numbers in SOD1 control), ##p,0.01, ### p,0.001 (compared with the number of large caliber axons in SOD1
control).
doi:10.1371/journal.pone.0037258.g006
Figure 7. DHT improves motoneuron survival in SOD1 mice. A: SOD1 mice were implanted with either a DHT-filled or an empty silastic
(control) tube at P75, and the lumbar spinal cord (L) 3-L5 was collected at P120, the symptomatic age. Cross-sectional pictures of the hemi-lumbar
spinal cord in WT, control SOD1, and DHT-treated SOD1 mice are shown. B: There was a 41% reduction in motoneuron number in the L3–L5 of SOD1
mice (13.960.7, n=5) compared with WT mice at P120 (23.860.9, n=4, p,0.0001). DHT-treated SOD1 mice contained 27% more motoneurons
(17.760.8, n=5, p=0.0093) compared with control SOD1 mice. In the cervical spinal cord, there were 45% less motoneurons in SOD1 mice (16.860.7,
n=3,p=0.015) compared with WT mice at P120 (30.661.5, n=3). There were 18% more motoneurons in DHT-treated SOD1 mice (19.960.4, n=3,
p=0.467) compared with control SOD1 mice. Data are mean 6 SEM. **p,0.01(compared with control SOD1 mice), #p,0.05, ### p,0.001
(compared with age-matched WT mice).
doi:10.1371/journal.pone.0037258.g007
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37258Figure 8. DHT improves motor performances and survival in SOD1 mice. A: SOD1 mice were implanted with either a DHT-filled or an empty
silastic (control) tube at P75, and their motor performances were assessed every 5 days by the rota-rod test. A mouse was placed on the rotating rod
at 11 rpm, and the latency until the mouse fell from the rotating rod was recorded in seconds. DHT-treated SOD1 mice (filled square, n=16) stayed
longer on the rotating rod compared with control SOD1 mice (empty circle, n=22). Data are mean 6 SEM. p=0.043 (2-way ANOVA). B: Hindlimbs
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kinase cascade, which lead to muscle growth [34].
DHT-mediated increase of IGF-1 in muscle as
a neurotrophic source through retrograde transport
In addition to the myotrophic effect of IGF-1, muscle-derived
IGF-1 can be retrogradely transported, and may contribute to
motoneuron survival. Indeed, IGF-1 is one of the most potent
neurotrophic factors tested in ALS model mice. Intramuscular
injection of IGF-1 carried by adeno-associated virus enabled
successful retrograde transport of IGF-1 to motoneurons, and
demonstrated pronounced effects in protecting motoneurons as
well as in delaying disease progression of ALS [52,53]. Moreover,
restricted expression of IGF-1 in skeletal muscle also protected
motoneurons through retrograde transport and increased lifespan
in ALS model mice [54], which further confirms the contribution
of muscle in ALS disease progression. Compared to the preclinical
studies utilizing viral vectors encoding IGF-1 for an efficient and
prolonged supply, this approach may not be easily translated to
patients due to difficulties regarding gene therapy. Although direct
injection of IGF-1 is a possible option, no significant effect in
survival had been found through this approach mainly due to the
short half-life of protein [55,56]. Moderate success was made
through intrathecal administrations of IGF-1 to patients, but
repetitive invasive injections in the spinal cord are required for
chronic delivery of IGF-1 [57]. Considering the difficulties in
delivery of IGF-1, endogenous increase of IGF-1 through DHT
treatment may have a significant meaning for translational studies.
Based on our study showing that DHT induced expression of IGF-
1 in skeletal muscle in SOD1-G93A mice, DHT treatment might
be an indirect but relatively non-invasive method to increase
endogenous IGF-1 expression in muscle, which can be retro-
gradely transported to motoneurons to promote neuronal survival.
It is possible that there might be an additional benefit of
retrogradely transported trophic factor as compared to the
centrally delivered factor because overexpressed GDNF in muscle
increased the motoneuron survival and delayed disease pro-
gression while overexpressed GDNF in astrocytes failed to show
beneficial effects in ALS model mice [58]. Similarly, viral vector-
mediated administration of IGF-1 directly into the spinal cord
failed to elicit a survival effect in a rat model of ALS despite
a protective effect on motoneuron survival [59]. Therefore, there
might be an additional benefit of retrograde transport, which
might be that muscle-derived trophic factors are likely to benefit
both motoneurons and muscle.
The neuroprotective effect of DHT
Besides the potential neuroprotective effect mediated by IGF-1,
androgens demonstrate effects in improving neuronal survival
through androgen receptors (ARs) [60]. Motoneurons in the spinal
cord express high level of ARs [15], and androgens increase
motoneuron survival in several experimental conditions. Andro-
gens increase motoneuron survival rate from 50% to 90% after
nerve injury in the avian embryonic lumbar spinal cord [61].
Similarly, increased motoneuron survival through androgen
treatment was observed in organotopic culture of the spinal cord
[62], as well as in neuroblastoma and motoneuron hybrid cells
[63]. Even in SBMA model mice expressing toxic mutant ARs,
normal ARs still play an important role in neuroprotection, thus
removing normal ARs can accelerate the neurodegeneration in
SBMA [64].
It is worth noting that the ventral horn of the spinal cord
expresses high levels of 5-a reductase [15,65], which converts
testosterone into DHT. Therefore, it is possible that DHT might
be the androgen inducing motoneuron survival in the spinal cord,
and we observed that DHT-treated SOD1-G93A mice contained
more motoneurons in the spinal cord than control SOD1-G93A
mice (Fig. 7). It is likely that DHT and AR-mediated pathway
together with muscle-derived IGF-1-mediated pathway contribut-
ed to increased motoneuron survival in SOD1-G93A mice. In
regard of a recent study demonstrating that DHT can be
converted to 3beta-Adiol, which activates the estrogen receptor
beta [66], we cannot exclude a possibility that ER-mediated
pathways might also contribute to the neuroprotective effect of
DHT.
Furthermore, androgen is known to increase the regeneration
rate of axons after peripheral nerve injury caused by axotomy
[16]. Therefore, improved NMJ innervation in the hindlimb of
DHT-treated SOD1-G93A mice might be mediated through the
beneficial effect of DHT on axonal regeneration. The increased
myelinated axon number observed in the nerves of DHT-treated
SOD1-G93A mice (Fig. 6) is also possibly mediated by DHT-
induced axonal regeneration, which might counteract dying-back
axonal degeneration.
Concerns regarding androgen treatment
Despite improved morphological phenotypes in skeletal muscle,
axons, and motoneurons observed in DHT-treated SOD1-G93A
mice, we found a relatively small effect on survival. It is possible
that DHT treatment may result in decreased fat storage, which
can be used as an energy source. In fact, hypermetabolism and
associated defects in energy homeostasis have been implicated in
ALS [67], and therefore high fat diet exerts beneficial effects in
delaying the disease progression of ALS [68,69]. However,
androgens are known to reduce fat through inhibiting adipogenesis
and increase muscle by enhancing myogenesis [70,71]. Since
DHT might affect fat storage, intake of a high fat diet might be
desirable to compensate the possible loss of fat storage as an energy
source.
Although molecular mechanisms need to be further elucidated,
considering the beneficial effects of DHT on multiple cell types
including muscle and neurons, DHT might be a potential
candidate as a multi-systemic drug for ALS involving neuronal
and non-neuronal cells in disease progression. In support of
a notion that targeting multiple cell types implicated in ALS might
be a potential therapeutic strategy, we have also demonstrated that
trichostatin A, which exerts beneficial effects on neurons, glia, and
muscle, delays the disease progression of ALS [72]. Considering
the fact that there is no effective drug for ALS patients to improve
were placed into non-toxic paints and a mouse was allowed to walk on a 50 cm- length of paper, and its continuous locomotion was recorded.
Representative footprints obtained from DHT-implanted or empty tube-implanted SOD1 mice at P100 are shown. DHT-treated SOD1 mouse (top
panel) showed a longer step length without a trace of dragging hindlimb compared with control SOD1 mice (bottom panel). C: Step length was
quantified by dividing walking distance by the number of the steps taken within the measured walking distance. DHT-treated SOD1 mice (filled
square, n=6) showed longer step length compared with control SOD1 mice (empty circle, n=7). p=0.003 (paired t-test). D: DHT-treated SOD1 mice
showed significantly increased survival duration after DHT administration by 11% in DHT-treated SOD1-G93A mice (82.962.9 days, n=18) compared
with age-matched control SOD1-G93A mice (74.862.2 days, n=24). E: DHT-treated SOD1 mice showed significantly increased the overall lifespan by
8 days (filled square, 157.962.9 days, n=18) compared with control SOD1 mice (empty circle, 149.862.2 days, n=24). p=0.0174 (log-rank test).
doi:10.1371/journal.pone.0037258.g008
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the present study may provide an initial step toward a possible
therapy for ALS. However, several concerns remain regarding
adverse side effects of chronic DHT treatment. Since DHT may
increase the incidence of benign prostate hyperplasia due to the
proliferative activity in the prostate [73], alternative androgens
that have almost no effect on the prostate such as selective
androgen receptor modulators (SARMs) [74] can be tested to see
whether they can replicate the effects of DHT in ALS. Since ALS
is a progressive disease that usually causes death within 2–3 years,
if the side effects are minor with DHT or SARMs, these
treatments might be tolerable.
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